ABSTRACT

A pharmaceutical combination comprises a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotope labeled form thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof and an α-glucosidase inhibitor. A pharmaceutical composition, a fixed dose combination formulation, a preparation method for and the use of the pharmaceutical composition and the fixed dose combination formulation.